|
BioVex is a biotechnology company focused on the development and commercialization
of biological treatments for cancer and the prevention of infectious
disease.
Our lead cancer program, OncoVEXGM-CSF, is a first in class oncolytic
vaccine or cancer destroying virus technology that works by replicating
and spreading within solid tumors, causing the death of cancer cells
while leaving surrounding healthy cells unharmed. The attenuated virus
has also been constructed to induce a powerful systemic anti tumor
immune response. OncoVEXGM-CSF has now been tested in >110 patients
in a broad range of solid tumors including melanoma, head & neck
cancer, breast cancer and pancreatic cancer. Both the direct cell killing
and systemic immune mediated mechanisms of action of OncoVEX have been
clearly validated in the clinic; OncoVEX routinely destroys tumors
it is directly injected into and has led to overall disease responses
in multiple patients in Phase II testing. Tumors resolved through OncoVEX
treatment have not been known to recur.
|
